Celldex Therapeutics (CLDX) Debt to Equity (2010 - 2013)

Celldex Therapeutics' Debt to Equity history runs 4 years deep, the most recent figure standing at $0.05 for Q1 2013.

• In Q1 2013, Debt to Equity fell 63.35% year-over-year to $0.05; the TTM figure through Mar 2013 stood at $0.05 (down 63.35% YoY), while the FY2012 annual figure was $0.12, down 46.28% from the prior year.
• Debt to Equity was $0.05 for Q1 2013 at Celldex Therapeutics, down from $0.12 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.22 in Q4 2011 to a low of $0.05 in Q1 2013.
• Historically, Debt to Equity has averaged $0.15 across 4 years, with a median of $0.14 in 2012.
• The sharpest annual moves came in 2011 and 2013: Debt to Equity surged 65.84% in 2011, then tumbled 63.35% in 2013.
• A 4-year view of Debt to Equity shows it stood at $0.13 in 2010, then soared by 65.84% to $0.22 in 2011, then tumbled by 46.28% to $0.12 in 2012, then slumped by 56.43% to $0.05 in 2013.
• The last three Debt to Equity figures came in at $0.05 (Q1 2013), $0.12 (Q4 2012), and $0.14 (Q3 2012), per Business Quant data.